Literature DB >> 21336821

Nicotine decreases beta-amyloid through regulating BACE1 transcription in SH-EP1-α4β2 nAChR-APP695 cells.

Hui-Zhen Nie1, Zuo-Qing Li, Qi-Xin Yan, Ze-Jian Wang, Wen-Juan Zhao, Ling-Chen Guo, Ming Yin.   

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder that affects the elderly population. Deposition of beta-amyloid (Aβ) in the brain is a hallmark of AD pathology. In our previous study, we have constructed a cell line expressing human APP695 (hAPP695) in SH-EP1 cells stably transfected with human nicotinic receptor (nAChR) α4 subunit and β2 subunit gene. In present study, we found that activation of α4β2 nAChR by nicotine and epibatidine decreased secreted Aβ level in the cell line and hippocampal neurons, but had no effects on full-length APP695 and sAPP-α. Nicotine also decreases BACE1 and PSEN1 expression, as well as ERK1 and NFκB P65 subunit expression in the cell line. Furthermore, BACE1 promoter activity is, but PSEN1 not, decreased by nicotine in the cell line. All the results suggest that activation of α4β2 nAChR decreases Aβ through regulating BACE1 transcription by ERK1-NFκB pathway. Additionally, analysis of BACE1 promoter activity by dual-luciferase reporter assay may be useful for drug screening as a high throughput method.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21336821     DOI: 10.1007/s11064-011-0420-7

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  31 in total

1.  Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease.

Authors:  Li-Bang Yang; Kristina Lindholm; Riqiang Yan; Martin Citron; Weiming Xia; Xiao-Li Yang; Thomas Beach; Lucia Sue; Philip Wong; Donald Price; Rena Li; Yong Shen
Journal:  Nat Med       Date:  2003-01       Impact factor: 53.440

2.  Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.

Authors:  Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

3.  Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides.

Authors:  Krystyn Z Bourne; Diana C Ferrari; Christine Lange-Dohna; Steffen Rossner; Thomas G Wood; J Regino Perez-Polo
Journal:  J Neurosci Res       Date:  2007-05-01       Impact factor: 4.164

4.  Cholinesterase activity and mRNA level of nicotinic acetylcholine receptors (alpha4 and beta2 Subunits) in blood of elderly Chinese diagnosed as Alzheimer's disease.

Authors:  Lan-Jian Zhang; Yan Xiao; Xiao-Lan Qi; Ke-Ren Shan; Jin-Jing Pei; Shi-Xiang Kuang; Fang Liu; Zhi-Zhong Guan
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 5.  Neuronal nicotinic receptors in the human brain.

Authors:  D Paterson; A Nordberg
Journal:  Prog Neurobiol       Date:  2000-05       Impact factor: 11.685

6.  cAMP targeting of p38 MAP kinase inhibits thrombin-induced NF-kappaB activation and ICAM-1 expression in endothelial cells.

Authors:  Arshad Rahman; Khandaker N Anwar; Mohd Minhajuddin; Kaiser M Bijli; Kamran Javaid; Andrea L True; Asrar B Malik
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2004-07-09       Impact factor: 5.464

Review 7.  BACE1: the beta-secretase enzyme in Alzheimer's disease.

Authors:  Robert Vassar
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 8.  Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory.

Authors:  Paul R Turner; Kate O'Connor; Warren P Tate; Wickliffe C Abraham
Journal:  Prog Neurobiol       Date:  2003-05       Impact factor: 11.685

9.  Long-term nicotine exposure-induced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and beta-adrenoceptors in human bladder cancer cells.

Authors:  Rong-Jane Chen; Yuan-Soon Ho; How-Ran Guo; Ying-Jan Wang
Journal:  Toxicol Sci       Date:  2010-01-27       Impact factor: 4.849

Review 10.  Current treatment and recent clinical research in Alzheimer's disease.

Authors:  Judith Neugroschl; Mary Sano
Journal:  Mt Sinai J Med       Date:  2010 Jan-Feb
View more
  3 in total

1.  Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.

Authors:  Megha Verma; David Beaulieu-Abdelahad; Ghania Ait-Ghezala; Rena Li; Fiona Crawford; Michael Mullan; Daniel Paris
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

2.  Low-Frequency Repetitive Transcranial Magnetic Stimulation Ameliorates Cognitive Function and Synaptic Plasticity in APP23/PS45 Mouse Model of Alzheimer's Disease.

Authors:  Zhilin Huang; Tao Tan; Yehong Du; Long Chen; Min Fu; Yanzhi Yu; Lu Zhang; Weihong Song; Zhifang Dong
Journal:  Front Aging Neurosci       Date:  2017-09-12       Impact factor: 5.750

Review 3.  Consequences of inhibiting amyloid precursor protein processing enzymes on synaptic function and plasticity.

Authors:  Hui Wang; Andrea Megill; Kaiwen He; Alfredo Kirkwood; Hey-Kyoung Lee
Journal:  Neural Plast       Date:  2012-06-26       Impact factor: 3.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.